-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
CoronaVac is an inactivated SARS-CoV-2 vaccine that has been approved for emergency use in many countries
.
However, its immunogenicity in immunodeficient individuals has not yet been fully clarified
immunity
Recently, a research article was published in the top medical journal Nature Medicine.
Researchers conducted a study among 910 adults with autoimmune rheumatism (ARD) and 182 healthy adults (control group, CG) with matching age and gender frequency.
In a prospective phase 4 controlled trial (no.
NCT04754698, CoronavRheum), they received two doses of CoronaVac vaccine
.
The main outcome of the study was that compared with the CG group, the ARD group was positive for anti-SARS-CoV-2 IgG seroconversion (SC) and neutralizing antibody (NAb) 6 weeks after the second injection (day 69 (D69)) Decrease ≥15%
.
The secondary outcome was IgG SC and NAb positivity at D28, IgG titers and neutralizing activity at D28, and vaccine safety at D69
Compared with the CG group, the anti-SARS-CoV-2 IgG SC (70.
4 vs.
95.
5%, P<0.
001) and NAb positive (56.
3 vs.
79.
3%, P<0.
001) in the ARD group at D69 reached the preset The end
.
In addition, ARD patients had lower IgG titers (12.
It can be seen that these data support CoronaVac vaccination for ARD patients, indicating that its short-term immunogenicity is reduced but acceptable
.
The trial is still ongoing to evaluate the long-term effectiveness/immunogenicity of CoronaVac vaccine in ARD patients
These data support the CoronaVac vaccine in ARD patients, indicating that its short-term immunogenicity is reduced but acceptable
Original source:
Medeiros-Ribeiro, et al.
Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial in this message
